Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.43 |
| ▸ | ITGAV | P06756 | 9/20 | 0.43 |
| ▸ | CASP1 | P29466 | 7/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7211505 | 0.94 | ITGB3 (0.42) | ITGB3ITGAVCASP1GRIN2BITGA2B | |
| SCHEMBL7217714 | 0.88 | ITGB3 (0.46) | ITGB3ITGAVCASP1ITGA2BITGB5 | |
| SCHEMBL7212704 | 0.88 | ITGB3 (0.42) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7212746 | 0.87 | ITGB3 (0.39) | ITGB3CASP1ITGA2BCTSL | |
| SCHEMBL7974387 | 0.86 | ITGB3 (0.37) | ITGB3ITGAVCASP1ITGA2BITGB5 | |
| SCHEMBL7211496 | 0.84 | ITGB3 (0.33) | ITGB3ITGAVCASP1ITGA2BITGB5 | |
| SCHEMBL7211648 | 0.84 | ITGB3 (0.52) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7212721 | 0.83 | ITGB3 (0.35) | ITGB3ITGAVCASP1ITGA2B | |
| SCHEMBL7216436 | 0.82 | ITGB3 (0.39) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7217610 | 0.82 | ITGB3 (0.47) | ITGB3ITGAVITGA2BITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620820-B2 | Imidazole dione or one, thione derivatives as antitumor and antiinflammatory agents, also treats cardiovascular disease, nephropathies and retinopathies | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-09-16 | — | — | US | disclosed |
| US-20020119999-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | HOECHST AKTIENGESELLSCHAFT | 2002-08-29 | — | — | US | disclosed |
| US-20010021708-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | WEHNER VOLKMAR (DE) | 2001-09-13 | — | — | US | disclosed |
| US-6218415-B1 | THERAPY OF BONE REABSORPTION BY OSTEOCLASTS, TUMOR GROWTH AND TUMOR METASTASIS, INFLAMMATION, CARDIOVASCULAR DISEASE, NEPHROPATHIES AND RETINOPATHIES | HOECHST AKTIENGESELLSCHAFT (DE) | 2001-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021708-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | ADGRF1, CALCR, SOST | ITGB3 500/4885ITGAV 478/4885CASP1 2981/4885 |
| US-20020119999-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | ADGRF1, CALCR, SOST | ITGB3 500/4885ITGAV 478/4885CASP1 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.